Why the study?
Diabetes is associated with unfavorable outcomes in AF patients, but few real-world data exist on the clinical performance of NOACs in this population.
Does Edoxaban reduce thromboembolic events and major bleedings compared to well-controlled vitamin K antagonists in patients with atrial fibrillation and diabetes mellitus?
Population
557 AF patients with diabetes (135 matched pairs evaluated)
Comparison
Edoxaban vs well-controlled VKAs
Design
Multicenter propensity score-matched cohort study
Follow-up
Mean 27 ± 3 months
Authors
Loading...
Edoxaban may confer favorable net clinical benefit versus well-controlled VKAs in diabetic AF; supports real-world use but leaves randomized confirmation open.
Does Edoxaban reduce thromboembolic events and major bleedings compared to well-controlled vitamin K antagonists in patients with atrial fibrillation and diabetes mellitus?
In a real-world cohort of patients with atrial fibrillation and diabetes, Edoxaban demonstrated comparable safety and effectiveness to well-controlled VKAs, with a favorable net clinical benefit.
Russo et al. (2020) studied this question.